Innovative Bioresearch Classic: Blockchain-Driven Biomedical Research and Data Sharing

What is Innovative Bioresearch Classic

Friends, imagine if medical research—especially those time-consuming, labor-intensive studies that require massive data support—could be as convenient and transparent as sharing photos online. Wouldn’t that be amazing? Innovative Bioresearch Classic (INNBCL for short) is such a project, aiming to bring blockchain technology into the field of biomedical research, particularly in HIV, cancer, and regenerative medicine.

Simply put, INNBCL is a digital token issued by the biotech company Innovative Bioresearch. This company is dedicated to developing new methods for HIV treatment and hopes to use decentralized approaches to handle clinical data. You can think of it as a “point” or “equity certificate” in the blockchain world for this company, used to support their research and ecosystem.

INNBCL is the company’s second token, with its “big brother” being INNBC (InnovativeBioresearchCoin), which is mainly used for HIV treatment research. INNBCL, on the other hand, focuses more on supporting cancer and regenerative medicine research projects.

Project Vision and Value Proposition

The core vision of the Innovative Bioresearch project is to use blockchain technology to solve issues of data storage, sharing, and transparency in traditional medical research. Imagine that current medical research data is like paper books scattered across different libraries—searching, sharing, and verifying is very troublesome. They hope to use blockchain to turn this data into a public, transparent, and tamper-proof “digital library,” making it easier for scientists worldwide to access and utilize.

They hope that this approach will accelerate the development of new drugs and treatment plans, especially for major diseases like HIV and cancer. Additionally, they plan to provide a decentralized social platform for the HIV-positive community, allowing people to support each other and share information.

Compared to traditional projects, Innovative Bioresearch stands out by combining biotech research with blockchain technology, aiming to create a decentralized clinical data processing solution and database—making it an early explorer in the DeSci (Decentralized Science) field.

Technical Features

The INNBCL token runs on the Ethereum platform. Ethereum is a very popular blockchain platform—you can think of it as a huge, globally shared “computer” where many cryptocurrencies and decentralized applications (DApps) operate.

The project’s core technical highlight is its developed decentralized application (DApp). This DApp acts like a special “digital notebook,” allowing researchers to securely record research data such as text, images, and even audio and video on the blockchain. Once data is recorded, it’s very hard to tamper with and can be publicly accessed by authorized individuals, greatly improving the transparency and credibility of research data. This model is designed to overcome the limitations of traditional centralized databases and enable better sharing of scientific data.

Tokenomics

The token symbol for INNBCL is INNBCL. It operates on the Ethereum blockchain.

Regarding the total and circulating supply, there are some discrepancies among different sources, which is not uncommon in the crypto space but requires special attention. According to Coinbase and Crypto.com, the maximum supply of INNBCL is 5 billion tokens. CoinMarketCap also shows a maximum supply of 5 billion, but its self-reported supply and circulating supply are higher. This inconsistency in data is something to be particularly mindful of when evaluating the project.

One of the main uses of the INNBCL token is that holders can receive airdrops and rewards of INNBC (the company’s main token). It’s like buying a company’s stock—besides the value of the stock itself, you can also get discounts or dividends on other company products. Additionally, the INNBC token (closely linked to INNBCL) can be used to purchase goods and services offered by the company’s partners.

As for specific token allocation and unlocking information, no detailed explanation is found in currently available public materials—this is usually covered in the whitepaper.

Team, Governance, and Funding

The key figure of the project is founder and CEO Jonathan Fior. He is not only a research scientist with deep expertise in HIV, cancer, and regenerative medicine, but also has a background in software development. He founded Innovative Bioresearch in 2014 and was among the first to introduce blockchain technology into scientific research in 2018, making him an early explorer in the decentralized science (DeSci) field.

Although the core team is small, Innovative Bioresearch collaborates with professional contract research organizations (CROs) to conduct experiments, allowing them to leverage external expertise to advance research. This model is like a small but elite R&D team that outsources experiments to improve efficiency.

Details about the project’s specific governance mechanisms (such as how token holders participate in decision-making) and treasury information are not clearly mentioned in the available materials.

Roadmap

The development of the Innovative Bioresearch project dates back to 2018, when they issued the INNBC token and were considered pioneers in decentralized science (DeSci). Subsequently, INNBCL was issued as a “sister coin” to support broader cancer and regenerative medicine research.

Key milestones include:

• 2018: INNBC token issued, introducing blockchain technology to scientific research.
• Early stage: Launched decentralized application (DApp) for biomedical data storage and sharing on the blockchain.
• Recent: Peer-reviewed research results on the INNBC DApp have been published on the Springer-Nature network, indicating scientific recognition of its technology.

Future plans may include:

• Further expansion of research areas.
• Development of the “You’re not alone” app, aiming to provide a decentralized database for research and potentially serve as a social platform for the HIV-positive community.
• Plans to launch the INNBC L1 chain, which may mean migrating from Ethereum to their own independent blockchain.

Common Risk Reminders

Any blockchain project comes with risks, and INNBCL is no exception. Here are some aspects to pay attention to:

• Information transparency risk: Although the project has an official website and some introductions, detailed whitepaper information about the INNBCL token itself (such as token allocation, unlocking plans, etc.) is incomplete in public materials. Additionally, there are discrepancies in token supply data across platforms, which may lead to information asymmetry.
• Technical and operational risk: User reviews have pointed out poor website experience, and its DApp may not be fully launched yet. Any new technology development and promotion comes with uncertainty, especially in the highly specialized and regulated biomedical field.
• Market and liquidity risk: INNBCL’s trading volume and market activity may be low, with some platforms showing its price as zero or lacking data. There are also comments noting that the token is listed on some “low-reputation” exchanges, which may affect its liquidity and security.
• Compliance risk: Biomedical research and blockchain technology are both strictly regulated. The project may face compliance challenges in different jurisdictions.
• Not investment advice: Remember, all the above information is not investment advice. The cryptocurrency market is highly volatile and risky—please do thorough personal research and make decisions according to your own risk tolerance.

Verification Checklist

• Block explorer contract address:
  • Ethereum contract address:
    0x0Cc9FCCFF81252F4bd8C5c6b359B14ae2Ed851cf
• GitHub activity: No direct information about the project’s GitHub activity was found in current search results.
• Official website:
  https://www.innovativebioresearch.com/
• Whitepaper: The official website and some crypto information platforms (such as Crypto.com) provide whitepaper links, but mainly mention the INNBC whitepaper. Detailed whitepaper information for INNBCL needs further verification.

Project Summary

Innovative Bioresearch Classic (INNBCL) is a token issued by the biotech company Innovative Bioresearch, aiming to apply blockchain technology to biomedical research, especially in HIV, cancer, and regenerative medicine. Its core concept is to create a decentralized database and application to improve the transparency, credibility, and sharing efficiency of medical research data, accelerating scientific discovery and treatment development. The project was founded by research scientist Jonathan Fior and has launched its token and decentralized application on the Ethereum platform.

However, when evaluating this project, it’s important to note some potential risks, such as insufficient token information transparency (especially detailed tokenomics for INNBCL), discrepancies in data across platforms, and possibly low market liquidity. While the project’s vision is ambitious, its specific implementation and market performance require ongoing attention.

In summary, INNBCL represents an interesting attempt to apply blockchain technology in the decentralized science (DeSci) field, aiming to address some pain points in traditional medical research. But like any emerging technology and crypto project, it also comes with uncertainty and risk. It is recommended to conduct thorough research and remain cautious before making any decisions. This is absolutely not investment advice.